Safety and Effectiveness of a Vaccine for Prostate Cancer That Uses Each Patients' Own Immune Cells.

Inclusion Criteria

• •Disease Characteristics
• •Histologically confirmed prostate carcinoma
• •Progressive, disease required, i.e.: elevated PSA documented to be rising on 3 occasions, either despite castrate testosterone levels (below 50 ng/dl), or after definitive local therapy (prostatectomy or radiation).
• •Prior/Concurrent Therapy
• •Biologic therapy:
• •Recovered from toxicity of any prior therapy
• •-Chemotherapy:
• •At least 4 weeks since chemotherapy -Endocrine evaluation/therapy
• •3 rising PSA values at least 2 weeks apart
• •At least 2 weeks since concurrent corticosteroids (other than for replacement therapy for adrenal insufficiency)
• •Medical hormonal therapy to maintain castrate testosterone levels permitted
• •-Radiotherapy:
• •At least 4 weeks since radiotherapy
• •-Surgery:
• •Prior surgery allowed
• •Patient Characteristics
• •Age: 18 and over, able to give written informed consent. Individuals unable to provide informed consent must have consent provided by the legal guardian, or person designated by the subject to give consent on his behalf.
• •Performance status: Karnofsky 70-100%
• •Life expectancy: At least 1 year
• •Hematopoietic: obtained twice, once within 45 days prior to study entry, and again within 72 hours of study entry.
• •WBC greater than 3,800
• •Absolute neutrophils greater than 1,500
• •Absolute lymphocytes greater than 500
• •Platelets greater than 120,000
• •Hb at least 10 g/dl
• •Hepatic:
• •--Bilirubin less than 2.0 mg/dl OR
• •--SGOT less than 2 x ULN
• •Renal:
• •* Creatinine no greater than 2.0 mg/dl OR
• •* Creatinine clearance at least 40 ml/min
• •Rheumatologic:
• •--ANA no greater than upper limit of normal, or ANA abnormal in absence of clinical signs of autoimmunity.
• •* Rheumatoid factor (RF) no greater than upper limit of normal, or RF abnormal in absence of clinical signs of autoimmunity.
• •* Anti-ds DNA no greater than upper limit of normal, or anti ds DNA abnormal in absence of clinical signs of autoimmunity.
• •Immunologic:
• •Influenza serology (assessment made at time of screening).
• •Assessment of DTH response to a standard anergy panel (to include candida, trichophyton and tetanus) or to a Multitest CMI (a disposable kit for DTH testing with standardized preloaded antigens).
• •Endocrine:
• •--TSH, T3, and T4 no greater than upper limit of normal
• •Radiographic:
• •* Baseline bone scan
• •* Baseline CT or MRI of abdomen and pelvis